Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won ...

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

The stock's fall snapped a two-day winning streak.

Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

This was the stock's second consecutive day of gains.